AbbVie Balances False Claims Act Risks With Alloy Antibody Collaboration - simplywall.st
AbbVie (NYSE:ABBV) is facing a revived whistleblower lawsuit alleging violations of the U.S. False Claims Act tied to federal drug pricing. The case brings renewed attention to AbbVie’s pricing pr...